These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

292 related articles for article (PubMed ID: 33936100)

  • 1. An Integrated Genomic, Proteomic, and Immunopeptidomic Approach to Discover Treatment-Induced Neoantigens.
    Olsson N; Heberling ML; Zhang L; Jhunjhunwala S; Phung QT; Lin S; Anania VG; Lill JR; Elias JE
    Front Immunol; 2021; 12():662443. PubMed ID: 33936100
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antigen presentation profiling reveals recognition of lymphoma immunoglobulin neoantigens.
    Khodadoust MS; Olsson N; Wagar LE; Haabeth OA; Chen B; Swaminathan K; Rawson K; Liu CL; Steiner D; Lund P; Rao S; Zhang L; Marceau C; Stehr H; Newman AM; Czerwinski DK; Carlton VE; Moorhead M; Faham M; Kohrt HE; Carette J; Green MR; Davis MM; Levy R; Elias JE; Alizadeh AA
    Nature; 2017 Mar; 543(7647):723-727. PubMed ID: 28329770
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunopeptidomics of colorectal cancer organoids reveals a sparse HLA class I neoantigen landscape and no increase in neoantigens with interferon or MEK-inhibitor treatment.
    Newey A; Griffiths B; Michaux J; Pak HS; Stevenson BJ; Woolston A; Semiannikova M; Spain G; Barber LJ; Matthews N; Rao S; Watkins D; Chau I; Coukos G; Racle J; Gfeller D; Starling N; Cunningham D; Bassani-Sternberg M; Gerlinger M
    J Immunother Cancer; 2019 Nov; 7(1):309. PubMed ID: 31735170
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analysis of the MHC class I antigen presentation machinery in human embryonal carcinomas: evidence for deficiencies in TAP, LMP and MHC class I expression and their upregulation by IFN-gamma.
    Seliger B; Dunn T; Schwenzer A; Casper J; Huber C; Schmoll HJ
    Scand J Immunol; 1997 Dec; 46(6):625-32. PubMed ID: 9420627
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interferon-gamma production in response to in vitro stimulation with collagen type II in rheumatoid arthritis is associated with HLA-DRB1(*)0401 and HLA-DQ8.
    Berg L; Rönnelid J; Sanjeevi CB; Lampa J; Klareskog L
    Arthritis Res; 2000; 2(1):75-84. PubMed ID: 11219392
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immune selection in murine tumors. Ph.d thesis.
    Svane IM; Engel AM
    APMIS Suppl; 2003; (106):1-46. PubMed ID: 12739251
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumor necrosis factor-alpha induces coordinated changes in major histocompatibility class I presentation pathway, resulting in increased stability of class I complexes at the cell surface.
    Hallermalm K; Seki K; Wei C; Castelli C; Rivoltini L; Kiessling R; Levitskaya J
    Blood; 2001 Aug; 98(4):1108-15. PubMed ID: 11493458
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HLA class I loss in metachronous metastases prevents continuous T cell recognition of mutated neoantigens in a human melanoma model.
    Schrörs B; Lübcke S; Lennerz V; Fatho M; Bicker A; Wölfel C; Derigs P; Hankeln T; Schadendorf D; Paschen A; Wölfel T
    Oncotarget; 2017 Apr; 8(17):28312-28327. PubMed ID: 28423700
    [TBL] [Abstract][Full Text] [Related]  

  • 9. LMP2+ proteasomes are required for the presentation of specific antigens to cytotoxic T lymphocytes.
    Sibille C; Gould KG; Willard-Gallo K; Thomson S; Rivett AJ; Powis S; Butcher GW; De Baetselier P
    Curr Biol; 1995 Aug; 5(8):923-30. PubMed ID: 7583150
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative study of the role of professional versus semiprofessional or nonprofessional antigen presenting cells in the rejection of vascularized organ allografts.
    Sundstrom JB; Ansari AA
    Transpl Immunol; 1995 Dec; 3(4):273-89. PubMed ID: 8665146
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Proteogenomic discovery of cancer antigens: Neoantigens and beyond.
    Kanaseki T; Tokita S; Torigoe T
    Pathol Int; 2019 Sep; 69(9):511-518. PubMed ID: 31397525
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Editing the immunopeptidome of melanoma cells using a potent inhibitor of endoplasmic reticulum aminopeptidase 1 (ERAP1).
    Koumantou D; Barnea E; Martin-Esteban A; Maben Z; Papakyriakou A; Mpakali A; Kokkala P; Pratsinis H; Georgiadis D; Stern LJ; Admon A; Stratikos E
    Cancer Immunol Immunother; 2019 Aug; 68(8):1245-1261. PubMed ID: 31222486
    [TBL] [Abstract][Full Text] [Related]  

  • 13. IFNγ Modulates the Immunopeptidome of Triple Negative Breast Cancer Cells by Enhancing and Diversifying Antigen Processing and Presentation.
    Goncalves G; Mullan KA; Duscharla D; Ayala R; Croft NP; Faridi P; Purcell AW
    Front Immunol; 2021; 12():645770. PubMed ID: 33968037
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Proteolysis and class I major histocompatibility complex antigen presentation.
    York IA; Goldberg AL; Mo XY; Rock KL
    Immunol Rev; 1999 Dec; 172():49-66. PubMed ID: 10631936
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ProGeo-neo: a customized proteogenomic workflow for neoantigen prediction and selection.
    Li Y; Wang G; Tan X; Ouyang J; Zhang M; Song X; Liu Q; Leng Q; Chen L; Xie L
    BMC Med Genomics; 2020 Apr; 13(Suppl 5):52. PubMed ID: 32241270
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MMP-7 derived peptides with MHC class-I binding motifs from canine mammary tumor tissue elicit strong antigen-specific T-cell responses in BALB/c mice.
    Yadav PK; Gupta SK; Kumar S; Ghosh M; Yadav BS; Kumar D; Kumar A; Saini M; Kataria M
    Mol Cell Biochem; 2021 Jan; 476(1):311-320. PubMed ID: 32970284
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Application of mass spectrometry-based MHC immunopeptidome profiling in neoantigen identification for tumor immunotherapy.
    Zhang X; Qi Y; Zhang Q; Liu W
    Biomed Pharmacother; 2019 Dec; 120():109542. PubMed ID: 31629254
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modulation of major histocompatibility complex Class I molecules and major histocompatibility complex-bound immunogenic peptides induced by interferon-alpha and interferon-gamma treatment of human glioblastoma multiforme.
    Yang I; Kremen TJ; Giovannone AJ; Paik E; Odesa SK; Prins RM; Liau LM
    J Neurosurg; 2004 Feb; 100(2):310-9. PubMed ID: 15086239
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Loss of interferon-gamma inducibility of the MHC class II antigen processing pathway in head and neck cancer: evidence for post-transcriptional as well as epigenetic regulation.
    Meissner M; Whiteside TL; van Kuik-Romein P; Valesky EM; van den Elsen PJ; Kaufmann R; Seliger B
    Br J Dermatol; 2008 May; 158(5):930-40. PubMed ID: 18284388
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunogenicity of human mesenchymal stem cells in HLA-class I-restricted T-cell responses against viral or tumor-associated antigens.
    Morandi F; Raffaghello L; Bianchi G; Meloni F; Salis A; Millo E; Ferrone S; Barnaba V; Pistoia V
    Stem Cells; 2008 May; 26(5):1275-87. PubMed ID: 18292209
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.